$239 Million is the total value of Opaleye Management Inc.'s 53 reported holdings in Q4 2015. The portfolio turnover from Q3 2015 to Q4 2015 was 36.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RARE | ULTRAGENYX PHARMACEUTICAL IN | $12,340,000 | +16.5% | 110,000 | 0.0% | 5.16% | -1.0% | |
| AXGN | AXOGEN INC | $10,600,000 | +21.4% | 2,120,000 | 0.0% | 4.43% | +3.1% | |
| FGEN | FIBROGEN INC | $9,903,000 | +39.0% | 325,000 | 0.0% | 4.14% | +18.1% | |
| GERN | GERON CORP | $8,833,000 | +75.4% | 1,825,000 | 0.0% | 3.69% | +49.0% | |
| MDGN | Buy | MEDGENICS INC | $8,368,000 | +1.1% | 1,390,000 | +31.3% | 3.50% | -14.1% |
| IMMY | IMPRIMIS PHARMACEUTICALS INC | $8,351,000 | +7.9% | 1,205,000 | 0.0% | 3.49% | -8.3% | |
| Buy | PROTALIX BIOTHERAPEUTICS INC | $8,262,000 | +92.4% | 8,100,000 | +122.5% | 3.45% | +63.5% | |
| OPHT | OPHTHOTECH CORP | $8,246,000 | +93.8% | 105,000 | 0.0% | 3.45% | +64.7% | |
| ARIA | ARIAD PHARMACEUTICALS INC | $8,188,000 | +7.0% | 1,310,000 | 0.0% | 3.42% | -9.1% | |
| EGRX | Buy | EAGLE PHARMACEUTICALS INC | $7,537,000 | +39.1% | 85,000 | +16.1% | 3.15% | +18.1% |
| Buy | INOTEK PHARMACEUTICALS CORP | $7,308,000 | +21.0% | 645,000 | +0.3% | 3.06% | +2.8% | |
| BPMC | Buy | BLUEPRINT MEDICINES CORP | $7,244,000 | +161.1% | 275,000 | +111.5% | 3.03% | +121.9% |
| CARA | Buy | CARA THERAPEUTICS INC | $7,199,000 | +21.4% | 427,000 | +2.9% | 3.01% | +3.2% |
| CDXS | Sell | CODEXIS INC | $6,768,000 | +23.2% | 1,600,000 | -1.2% | 2.83% | +4.7% |
| RTRX | Sell | RETROPHIN INC | $6,655,000 | -11.2% | 345,000 | -6.8% | 2.78% | -24.6% |
| RLYP | New | RELYPSA INC | $6,235,000 | – | 220,000 | +100.0% | 2.61% | – |
| CEMP | Sell | CEMPRA INC | $6,226,000 | -37.9% | 200,000 | -44.4% | 2.60% | -47.2% |
| SAGE | Buy | SAGE THERAPEUTICS INC | $5,830,000 | +589.1% | 100,000 | +400.0% | 2.44% | +486.1% |
| SUPN | Sell | SUPERNUS PHARMACEUTICALS INC | $5,645,000 | -12.5% | 420,000 | -8.7% | 2.36% | -25.7% |
| DEPO | New | DEPOMED INC | $5,439,000 | – | 300,000 | +100.0% | 2.27% | – |
| ADMS | Buy | ADAMAS PHARMACEUTICALS INC | $5,380,000 | +93.9% | 190,000 | +14.7% | 2.25% | +64.8% |
| AMAG | Sell | AMAG PHARMACEUTICALS INC | $4,529,000 | -43.0% | 150,000 | -25.0% | 1.89% | -51.6% |
| TNXP | Sell | TONIX PHARMACEUTICALS HLDG C | $4,334,000 | +43.7% | 565,000 | -0.9% | 1.81% | +22.1% |
| AVGR | Buy | AVINGER INC | $4,315,000 | +67.6% | 190,000 | +8.6% | 1.80% | +42.4% |
| AFMD | Buy | AFFIMED N V | $4,236,000 | +16.3% | 595,000 | +0.8% | 1.77% | -1.2% |
| FOMX | Buy | FOAMIX PHARMACEUTICALS LTD | $4,055,000 | +94.1% | 500,000 | +75.4% | 1.70% | +64.9% |
| Sell | CYTRX CORP | $3,816,000 | +5.6% | 1,440,000 | -5.6% | 1.60% | -10.3% | |
| New | LA JOLLA PHARMACEUTICAL CO | $3,780,000 | – | 140,000 | +100.0% | 1.58% | – | |
| TGTX | Buy | TG THERAPEUTICS INC | $3,579,000 | +36.6% | 300,000 | +15.4% | 1.50% | +16.0% |
| INTEC PHARMA LTD JERUSALEM | $3,377,000 | -4.3% | 630,000 | 0.0% | 1.41% | -18.7% | ||
| AMRN | AMARIN CORP PLCspons adr new | $3,326,000 | -2.1% | 1,760,000 | 0.0% | 1.39% | -16.8% | |
| NBIX | Sell | NEUROCRINE BIOSCIENCES INC | $3,111,000 | -37.4% | 55,000 | -56.0% | 1.30% | -46.8% |
| FLML | Sell | FLAMEL TECHNOLOGIES SAsponsored adr | $3,053,000 | -39.6% | 250,000 | -19.4% | 1.28% | -48.7% |
| AGRX | Sell | AGILE THERAPEUTICS INC | $2,928,000 | +12.8% | 300,000 | -22.1% | 1.22% | -4.2% |
| CORI | New | CORIUM INTL INC | $2,883,000 | – | 355,000 | +100.0% | 1.20% | – |
| Sell | TRILLIUM THERAPEUTICS INC | $2,648,000 | -17.1% | 210,000 | -14.4% | 1.11% | -29.6% | |
| XENE | Buy | XENON PHARMACEUTICALS INC | $2,412,000 | +93.0% | 300,000 | +98.3% | 1.01% | +63.9% |
| XOMA | Sell | XOMA CORP DEL | $2,261,000 | +1.9% | 1,700,000 | -42.4% | 0.94% | -13.4% |
| ZGNX | Sell | ZOGENIX INC | $2,211,000 | -34.5% | 150,000 | -40.0% | 0.92% | -44.4% |
| ALDR | Buy | ALDER BIOPHARMACEUTICALS INC | $2,147,000 | +307.4% | 65,000 | +303.7% | 0.90% | +246.7% |
| NBRV | New | NABRIVA THERAPEUTICS AGsponsored adr | $2,116,000 | – | 220,000 | +100.0% | 0.88% | – |
| EARS | Buy | AURIS MED HLDG AG | $1,834,000 | +45.1% | 375,000 | +5.6% | 0.77% | +23.3% |
| TENX | Sell | TENAX THERAPEUTICS INC | $1,771,000 | -7.0% | 540,000 | -15.0% | 0.74% | -21.0% |
| CYNA | Buy | CYNAPSUS THERAPEUTICS INC | $1,682,000 | +258.6% | 110,000 | +279.3% | 0.70% | +204.3% |
| AXDX | Sell | ACCELERATED DIAGNOSTICS INC | $1,612,000 | +4.9% | 75,000 | -21.1% | 0.67% | -10.8% |
| CLLS | New | CELLECTIS S Asponsored ads | $1,552,000 | – | 50,000 | +100.0% | 0.65% | – |
| MGNX | New | MACROGENICS INC | $1,084,000 | – | 35,000 | +100.0% | 0.45% | – |
| VTAE | New | VITAE PHARMACEUTICALS INC | $1,059,000 | – | 58,500 | +100.0% | 0.44% | – |
| IMMU | New | IMMUNOMEDICS INC | $890,000 | – | 290,000 | +100.0% | 0.37% | – |
| New | ACHAOGEN INC | $718,000 | – | 125,000 | +100.0% | 0.30% | – | |
| SGMO | New | SANGAMO BIOSCIENCES INC | $548,000 | – | 60,000 | +100.0% | 0.23% | – |
| EVOK | Sell | EVOKE PHARMA INC | $429,000 | -43.3% | 130,000 | -50.0% | 0.18% | -52.0% |
| BLRX | BIOLINERX LTDsponsored adr | $325,000 | -15.1% | 250,000 | 0.0% | 0.14% | -27.7% | |
| Exit | TRACON PHARMACEUTICALS INC | $0 | – | -12,172 | -100.0% | -0.06% | – | |
| CELGZ | Exit | CELGENE CORPrights 12/31/2030 | $0 | – | -340,000 | -100.0% | -0.27% | – |
| INNL | Exit | INNOCOLL AGsponsored adr | $0 | – | -55,543 | -100.0% | -0.34% | – |
| NVLS | Exit | NIVALIS THERAPEUTICS INC | $0 | – | -175,200 | -100.0% | -1.12% | – |
| MNTA | Exit | MOMENTA PHARMACEUTICALS INC | $0 | – | -160,000 | -100.0% | -1.29% | – |
| ZSPH | Exit | ZS PHARMA INC | $0 | – | -95,000 | -100.0% | -3.07% | – |
| CMRX | Exit | CHIMERIX INC | $0 | – | -310,000 | -100.0% | -5.83% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-02-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CODEXIS INC | 39 | Q3 2023 | 10.9% |
| CHIMERIX INC | 31 | Q3 2022 | 16.4% |
| XOMA CORP DEL | 27 | Q3 2023 | 3.6% |
| FIBROGEN INC | 26 | Q1 2021 | 6.8% |
| BIOLINERX LTD (Does not reflect a reverse stock split effectuated after June 30, 2019) | 26 | Q1 2020 | 2.4% |
| OCULAR THERAPEUTIX INC | 24 | Q3 2023 | 17.6% |
| AXOGEN INC | 20 | Q4 2019 | 18.7% |
| ETON PHARMACEUTICALS INC | 20 | Q3 2023 | 5.6% |
| AMARIN CORP PLC | 20 | Q4 2020 | 6.6% |
| IMPRIMIS PHARMACEUTICALS INC | 19 | Q1 2020 | 5.9% |
View Opaleye Management Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CHIMERIX INCSold out | February 13, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc. | January 23, 2023 | 1,560,000 | 3.6% |
| TELA Bio, Inc. | June 10, 2022 | 1,557,500 | 10.7% |
| Gemini Therapeutics, Inc. /DESold out | February 01, 2022 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | January 26, 2022 | 0 | 0.0% |
| AVENUE THERAPEUTICS, INC. | February 12, 2021 | 9 | 11.0% |
| Cardiff Oncology, Inc. | February 12, 2021 | 9 | 11.0% |
| EDAP TMS SA | February 12, 2021 | 9 | 11.0% |
| Fortress Biotech, Inc. | February 12, 2021 | 9 | 11.0% |
| Gemini Therapeutics, Inc. /DE | February 12, 2021 | 9 | 11.0% |
View Opaleye Management Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-25 |
| 4 | 2024-04-24 |
| 4 | 2024-04-19 |
| SC 13G/A | 2024-04-09 |
| SC 13G | 2024-04-08 |
| 4 | 2024-03-28 |
| 4 | 2024-03-22 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Opaleye Management Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.